BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor
Nora Sahnane(University of Insubria), Maria Grazia Tibiletti(University of Insubria), Fausto Sessa(University of Insubria), Annamaria Salvati(University of Salerno), Domenico Memoli(Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona), Jvan Casarin(University of Insubria), Francesca Rizzo(University of Salerno), Sofia Facchi(University of Insubria), Giorgio Formenti(University of Insubria), Eleonora Di Lauro(Ospedale di Circolo e Fondazione Macchi), R Bombelli(University of Insubria), Ileana Carnevali(University of Insubria)
Cited by 55
Related Papers
Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database
|Genetics in Medicine|2019|666
Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers
|Oncotarget|2016|309
Genomic and expression profiling identifies the B‐cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma
|British Journal of Haematology|2005|193
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
|Blood|2010|189
Inheritance in idiopathic premature ovarian failure: analysis of 71 cases
|Human Reproduction|1998|166